Insmed, First Solar, and Aptiv Form Death Cross, Signaling Bearish Trends
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 06 2026
0mins
Should l Buy INSM?
Source: stocktwits
- Death Cross Signal: Insmed, First Solar, and Aptiv have all formed a death cross, where the 50-day moving average falls below the 200-day, indicating a potential long-term downtrend, leading to a broadly bearish sentiment among retail investors, which could trigger further selling pressure.
- Insmed's Strong Performance: Despite the death cross formation, Insmed's stock remains about 8% above its 200-day moving average, and has surged over 12% since reporting positive results for Arikayce, with analysts projecting a strong buy consensus and a price target of $214.32, suggesting a potential upside of approximately 32%.
- First Solar's Challenges: First Solar's stock has dropped over 7% since its February earnings report, with the spread between its 50-day and 200-day moving averages exceeding 2%, indicating a well-established death cross; analysts have set a price target of $250.57, implying about 28% upside, but ongoing uncertainty in U.S. energy policy remains a concern.
- Aptiv's Structural Shift: Aptiv has faced a dual blow from tariff hikes and the removal of EV tax incentives, leading to a 6% decline in stock price, although it has gained over 20% in the past year; the death cross is firmly in place, with analysts targeting $92.43, indicating a potential upside of around 51%, while the upcoming spin-off of its electrical business may impact market reactions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INSM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INSM
Wall Street analysts forecast INSM stock price to rise
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 144.480
Low
162.00
Averages
219.50
High
263.00
Current: 144.480
Low
162.00
Averages
219.50
High
263.00
About INSM
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Insmed Halts Lung Disorder Therapy R&D Program After Trial Failure
- R&D Program Halted: Insmed announced the suspension of its lung disorder therapy brensocatib's R&D following a mid-stage trial failure against hidradenitis suppurativa, indicating that the drug did not meet primary or secondary efficacy endpoints, which could impact the company's future product pipeline.
- Trial Results Underwhelming: In the Phase 2b CEDAR study, both 10 mg and 40 mg doses failed to meet key goals, although patients tolerated the experimental therapy well with no new safety signals, potentially shaking investor confidence in the company's R&D capabilities.
- Contribution to Scientific Understanding: Despite the disappointing results, Insmed's medical chief, Martina Flammer, expressed hope that insights gained from this study will contribute to the broader scientific understanding of hidradenitis suppurativa, demonstrating the company's ongoing commitment to scientific research.
- Market Reaction: The suspension of this R&D program may negatively affect Insmed's stock price, especially after the company secured approval for brensocatib as a treatment for non-cystic fibrosis bronchiectasis in 2025, leading investors to reassess the company's market outlook.
See More
Insmed Halts Brinsupri Development for HS After Trial Failure
- Trial Failure: Insmed has halted the development of Brinsupri for hidradenitis suppurativa (HS) after it failed to meet efficacy endpoints in a mid-stage trial, with both 10mg and 40mg doses not outperforming placebo, indicating significant challenges for the company's future R&D direction.
- Efficacy Data Disclosure: The CEDAR study revealed that Brinsupri achieved only a 45.5% and 40.3% reduction in abscess and nodule counts, respectively, compared to a 57.1% reduction in the placebo group, failing to meet both primary and secondary endpoints, which poses a substantial challenge to Insmed's market confidence.
- Market Expansion Setback: Despite receiving approval in 2025 for non-cystic fibrosis bronchiectasis, this failure may hinder Brinsupri's expansion plans in the HS market, as analysts believe there is insufficient preclinical evidence to support the drug's mechanism of action in HS.
- Analyst Sentiment: Analysts generally believe that the trial results will not significantly impact investor sentiment towards Insmed, instead shifting focus to Brinsupri's market performance in bronchiectasis, with projections indicating potential sales of $5.5 billion by 2031.
See More
Insmed Discontinues Brensocatib Development After Phase 2b Study Fails
- Clinical Trial Results: Insmed Inc. announced that its Phase 2b CEDAR study evaluating brensocatib for moderate to severe hidradenitis suppurativa failed to meet primary and secondary efficacy endpoints in both the 10 mg and 40 mg treatment arms, leading to the discontinuation of the drug's development, indicating limited market prospects for this indication.
- Safety Profile: Despite the lack of efficacy, brensocatib was well tolerated across both doses with no new safety signals identified, particularly in the 40 mg arm, which may provide a foundation for potential development in other indications in the future.
- Efficacy Comparison: At Week 16, participants in the 10 mg arm experienced a 45.5% reduction in total abscess and inflammatory nodule (AN) count, while the 40 mg arm saw a 40.3% reduction; in contrast, the placebo group recorded a 57.1% reduction, highlighting brensocatib's inability to outperform placebo, which affects its competitive position in the market.
- Stock Price Reaction: Insmed's stock closed at $163.03 on Tuesday, down $0.78 (0.48%), but rose to $166.52 in after-hours trading, an increase of $3.49 (2.14%), reflecting cautious optimism among investors regarding the company's future developments.
See More
Insmed Discontinues Brensocatib HS Program After Phase 2b Study Fails
- Clinical Trial Failure: Insmed announced that its Phase 2b CEDAR study of brensocatib for moderate to severe hidradenitis suppurativa did not meet primary or secondary efficacy endpoints, leading to the decision to discontinue the program, highlighting significant R&D challenges in this area.
- Stable Safety Profile: Despite the lack of efficacy, brensocatib was well tolerated across both the 10 mg and 40 mg doses, with no new safety signals identified, indicating that the drug maintains a certain potential in terms of safety.
- Patient Response Data: In the 16-week study, the brensocatib 10 mg and 40 mg groups experienced reductions of 45.5% and 40.3% in total abscess and inflammatory nodule counts, respectively, compared to a 57.1% reduction in the placebo group, demonstrating some symptomatic improvement but insufficient to justify further development.
- Future Research Directions: Insmed intends to present the data from the CEDAR study at future congresses, and while the results are disappointing, the company hopes that insights gained will contribute to the broader scientific understanding of hidradenitis suppurativa.
See More
Insmed's Investigational Treatment for Skin Disease Falls Short in Clinical Trial
Trial Results: Insmed's mid-stage study evaluating brensocatib in adult patients with moderate to severe hidradenitis suppurativa failed to meet its primary and secondary endpoints.
Drug Tolerance: Despite the trial's failure, the drug was reported to be well tolerated among participants.
Future Development: Insmed announced plans to discontinue the development of brensocatib for hidradenitis suppurativa.
Condition Overview: Hidradenitis suppurativa is a chronic, non-contagious inflammatory skin condition characterized by painful, recurring lumps and abscesses.
See More
INSMED INC - PHASE 2B CEDAR STUDY OF BRENSOCATIB FAILED TO ACHIEVE EFFICACY GOALS
- Study Findings: The study on Bren's catib did not meet the expected efficacy endpoints.
- Implications: The results may impact future research and development in the relevant field.
See More
Insmed Halts Lung Disorder Therapy R&D Program After Trial Failure
- R&D Program Halted: Insmed announced the suspension of its lung disorder therapy brensocatib's R&D following a mid-stage trial failure against hidradenitis suppurativa, indicating that the drug did not meet primary or secondary efficacy endpoints, which could impact the company's future product pipeline.
- Trial Results Underwhelming: In the Phase 2b CEDAR study, both 10 mg and 40 mg doses failed to meet key goals, although patients tolerated the experimental therapy well with no new safety signals, potentially shaking investor confidence in the company's R&D capabilities.
- Contribution to Scientific Understanding: Despite the disappointing results, Insmed's medical chief, Martina Flammer, expressed hope that insights gained from this study will contribute to the broader scientific understanding of hidradenitis suppurativa, demonstrating the company's ongoing commitment to scientific research.
- Market Reaction: The suspension of this R&D program may negatively affect Insmed's stock price, especially after the company secured approval for brensocatib as a treatment for non-cystic fibrosis bronchiectasis in 2025, leading investors to reassess the company's market outlook.
See More
Insmed Halts Brinsupri Development for HS After Trial Failure
- Trial Failure: Insmed has halted the development of Brinsupri for hidradenitis suppurativa (HS) after it failed to meet efficacy endpoints in a mid-stage trial, with both 10mg and 40mg doses not outperforming placebo, indicating significant challenges for the company's future R&D direction.
- Efficacy Data Disclosure: The CEDAR study revealed that Brinsupri achieved only a 45.5% and 40.3% reduction in abscess and nodule counts, respectively, compared to a 57.1% reduction in the placebo group, failing to meet both primary and secondary endpoints, which poses a substantial challenge to Insmed's market confidence.
- Market Expansion Setback: Despite receiving approval in 2025 for non-cystic fibrosis bronchiectasis, this failure may hinder Brinsupri's expansion plans in the HS market, as analysts believe there is insufficient preclinical evidence to support the drug's mechanism of action in HS.
- Analyst Sentiment: Analysts generally believe that the trial results will not significantly impact investor sentiment towards Insmed, instead shifting focus to Brinsupri's market performance in bronchiectasis, with projections indicating potential sales of $5.5 billion by 2031.
See More
Insmed Discontinues Brensocatib Development After Phase 2b Study Fails
- Clinical Trial Results: Insmed Inc. announced that its Phase 2b CEDAR study evaluating brensocatib for moderate to severe hidradenitis suppurativa failed to meet primary and secondary efficacy endpoints in both the 10 mg and 40 mg treatment arms, leading to the discontinuation of the drug's development, indicating limited market prospects for this indication.
- Safety Profile: Despite the lack of efficacy, brensocatib was well tolerated across both doses with no new safety signals identified, particularly in the 40 mg arm, which may provide a foundation for potential development in other indications in the future.
- Efficacy Comparison: At Week 16, participants in the 10 mg arm experienced a 45.5% reduction in total abscess and inflammatory nodule (AN) count, while the 40 mg arm saw a 40.3% reduction; in contrast, the placebo group recorded a 57.1% reduction, highlighting brensocatib's inability to outperform placebo, which affects its competitive position in the market.
- Stock Price Reaction: Insmed's stock closed at $163.03 on Tuesday, down $0.78 (0.48%), but rose to $166.52 in after-hours trading, an increase of $3.49 (2.14%), reflecting cautious optimism among investors regarding the company's future developments.
See More
Insmed Discontinues Brensocatib HS Program After Phase 2b Study Fails
- Clinical Trial Failure: Insmed announced that its Phase 2b CEDAR study of brensocatib for moderate to severe hidradenitis suppurativa did not meet primary or secondary efficacy endpoints, leading to the decision to discontinue the program, highlighting significant R&D challenges in this area.
- Stable Safety Profile: Despite the lack of efficacy, brensocatib was well tolerated across both the 10 mg and 40 mg doses, with no new safety signals identified, indicating that the drug maintains a certain potential in terms of safety.
- Patient Response Data: In the 16-week study, the brensocatib 10 mg and 40 mg groups experienced reductions of 45.5% and 40.3% in total abscess and inflammatory nodule counts, respectively, compared to a 57.1% reduction in the placebo group, demonstrating some symptomatic improvement but insufficient to justify further development.
- Future Research Directions: Insmed intends to present the data from the CEDAR study at future congresses, and while the results are disappointing, the company hopes that insights gained will contribute to the broader scientific understanding of hidradenitis suppurativa.
See More
Insmed's Investigational Treatment for Skin Disease Falls Short in Clinical Trial
Trial Results: Insmed's mid-stage study evaluating brensocatib in adult patients with moderate to severe hidradenitis suppurativa failed to meet its primary and secondary endpoints.
Drug Tolerance: Despite the trial's failure, the drug was reported to be well tolerated among participants.
Future Development: Insmed announced plans to discontinue the development of brensocatib for hidradenitis suppurativa.
Condition Overview: Hidradenitis suppurativa is a chronic, non-contagious inflammatory skin condition characterized by painful, recurring lumps and abscesses.
See More
INSMED INC - PHASE 2B CEDAR STUDY OF BRENSOCATIB FAILED TO ACHIEVE EFFICACY GOALS
- Study Findings: The study on Bren's catib did not meet the expected efficacy endpoints.
- Implications: The results may impact future research and development in the relevant field.
See More
